RESULTS	After 84 months of median follow-up time , the IFN alpha 2b group gained a mean of 8.9 months without disease relapse ( P = .03 ) and 7.0 months of overall survival ( P = .07 ) as compared with the observation group , but had severe treatment-related toxicity for 5.8 months , on average .\